I listened to the latest presentation (Q&A not webccast). It sure sounded like the new business plan is to license the entire pipeline and get out of the research business. That would make the CFO a key player.
I'd be pitching Azixa mostly to Roche; a combination with Avastin looks extremely attractive in principle (but very expensive to develop). Of the active programs, I'd be pushing hardest to license the metabolism inhibitor: the other two have the potential to become a lot more valuable than they presently are with a little more research.
This train wreck makes me appreciate Incyte a lot more. Their stock is way off, but starting from the same sort of discovery program, and with a lot less seed money, they're getting two drugs to market [almost] for sure. The key seems to be that their technical leader is almost as good a money guy as the real money guys.